A - NYSE

Agilent Technologies, Inc.

A·NYSE

$137.40

+0.99%

HealthcareMedical - Diagnostics & Research

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$38.83B

EPS4.5900

P/E Ratio29.93

Earnings Date08/26/2026

12.73B

Assets

3Y+21.0%

5Y+32.0%

10Y+63.0%

5.99B

Total Liabilities

3Y+15.0%

5Y+26.0%

10Y+69.0%

6.74B

Total Equity

14%

3Y+27.0%

5Y+38.0%

10Y+59.0%

Agilent Technologies, Inc. Funding & Solvency Profile

A · NYSE

Current Assets

Cash & Cash Equivalents1.79B

Net Receivables1.49B

Inventory1.02B

Other Current Assets293.00M

Total Current Assets5 B

Non-Current Assets

Property, Plant & Equipment2.02B

Goodwill & Intangible Assets4.92B

Long-Term Investments133.00M

Other Non-Current Assets1.06B

Total Non-Current Assets3 B

Total Assets

12.73B

Financial Health Analysis

Current Ratio

1.96x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.89x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

2 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

36% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Agilent Technologies, Inc. Balance Sheet

A • NYSE

Agilent Technologies, Inc. Balance Sheet	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021	Oct 2020	Oct 2019	Oct 2018	Oct 2017	Oct 2016	Oct 2015	Oct 2014	Oct 2013	Oct 2012	Oct 2011	Oct 2010	Oct 2009	Oct 2008	Oct 2007	Oct 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	1.8B	1.3B	1.6B	1.1B	1.5B	1.4B	1.4B	2.2B	2.7B	2.3B	2B	2.2B	2.7B	2.4B	3.5B	2.6B	2.5B	1.4B	1.8B	2.3B
Short-Term Investments	0.0	0.0	0.0	0.0	91M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14M	24M	0.0	0.0
Cash & Short-Term Investments	1.8B	1.3B	1.6B	1.1B	1.6B	1.4B	1.4B	2.2B	2.7B	2.3B	2B	2.2B	2.7B	2.4B	3.5B	2.6B	2.5B	1.4B	1.8B	2.3B
Net Receivables	1.5B	1.3B	1.3B	1.4B	1.2B	1B	930M	776M	724M	631M	606M	626M	899M	923M	860M	869M	595M	770M	735M	692M
Accounts Receivables	1.5B	1.3B	1.3B	1.4B	1.2B	1B	930M	776M	724M	631M	606M	626M	899M	923M	860M	869M	595M	770M	735M	692M
Inventory	1B	991M	1B	1B	830M	720M	679M	638M	575M	533M	541M	574M	1.1B	1B	898M	716M	552M	646M	643M	627M
Other Current Assets	293M	315M	274M	282M	222M	216M	198M	187M	192M	182M	536M	2.1B	343M	341M	284M	1.9B	321M	337M	467M	377M
Total Current Assets	4.6B	4B	4.2B	3.8B	3.8B	3.4B	3.2B	3.8B	4.2B	3.6B	3.7B	5.5B	5B	4.6B	5.6B	6.2B	4B	3.2B	3.7B	4B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2B	2B	1.4B	1.1B	945M	845M	850M	822M	757M	639M	604M	631M	1.1B	1.2B	1B	980M	845M	824M	801M	775M
Goodwill	4.5B	4.5B	4B	4B	4B	3.6B	3.6B	3B	2.6B	2.5B	2.4B	2.5B	3B	3B	1.6B	1.5B	655M	646M	736M	385M
Intangible Assets	445M	547M	475M	821M	981M	831M	1.1B	491M	361M	408M	445M	649M	916M	1.1B	429M	494M	167M	228M	0.0	83M
Goodwill & Intangible Assets	4.9B	5B	4.4B	4.8B	5B	4.4B	4.7B	3.5B	3B	2.9B	2.8B	3.2B	4B	4.1B	2B	2B	822M	874M	736M	468M
Long-Term Investments	133M	175M	164M	195M	185M	158M	102M	68M	138M	135M	86M	96M	139M	109M	117M	142M	163M	206M	0.0	0.0
Tax Assets	0.0	436M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.1B	297M	554M	686M	820M	776M	611M	339M	397M	452M	289M	1.4B	481M	523M	369M	455M	1.8B	1.9B	2.3B	2.2B
Total Non-Current Assets	8.1B	7.9B	6.6B	6.8B	6.9B	6.2B	6.3B	4.7B	4.3B	4.2B	3.8B	5.3B	5.7B	5.9B	3.5B	3.5B	3.7B	3.8B	3.9B	3.4B
Total Assets	12.7B	11.8B	10.8B	10.5B	10.7B	9.6B	9.5B	8.5B	8.4B	7.8B	7.5B	10.8B	10.7B	10.5B	9.1B	9.7B	7.6B	7B	7.6B	7.4B
LIABILITIES
CURRENT LIABILITIES
Total Payables	570M	540M	418M	580M	446M	354M	354M	340M	305M	257M	279M	302M	432M	461M	472M	499M	307M	436M	323M	378M
Accounts Payable	570M	540M	418M	580M	446M	354M	354M	340M	305M	257M	279M	302M	432M	461M	472M	499M	307M	308M	323M	378M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	128M	0.0	0.0
Accrued Expenses	406M	398M	309M	329M	328M	285M	440M	203M	181M	184M	218M	279M	330M	375M	299M	725M	530M	614M	137M	131M
Short Term Debt	304M	45M	0.0	36M	0.0	75M	616M	0.0	210M	0.0	0.0	0.0	0.0	250M	253M	1.5B	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	42M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	73M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26M	0.0	0.0	0.0
Deferred Revenue	624M	544M	505M	461M	441M	386M	336M	324M	291M	269M	258M	260M	439M	420M	389M	358M	285M	280M	249M	225M
Other Current Liabilities	443M	326M	371M	455M	493M	367M	334M	304M	276M	235M	221M	851M	401M	387M	424M	0.0	0.0	0.0	954M	804M
Total Current Liabilities	2.3B	1.9B	1.6B	1.9B	1.7B	1.5B	2.1B	1.2B	1.3B	945M	976M	1.7B	1.6B	1.9B	1.8B	3.1B	1.1B	1.3B	1.7B	1.5B
NON-CURRENT LIABILITIES
Long Term Debt	3.1B	3.3B	2.7B	2.7B	2.7B	2.3B	1.8B	1.8B	1.8B	1.9B	1.7B	1.7B	2.7B	2.1B	1.9B	2.2B	2.9B	2.1B	2.1B	1.5B
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	182M
Other Non-Current Liabilities	589M	566M	580M	633M	879M	1B	833M	1B	527M	699M	678M	2.2B	1.1B	1.3B	972M	1.2B	1.1B	993M	570M	490M
Total Non-Current Liabilities	3.6B	4.1B	3.3B	3.4B	3.6B	3.3B	2.6B	2.8B	2.3B	2.6B	2.3B	3.8B	3.8B	3.5B	2.9B	3.4B	4B	3.1B	2.7B	2.2B
Capital Lease Obligations	0.0	184M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	6B	5.9B	4.9B	5.2B	5.3B	4.8B	4.7B	4B	3.6B	3.5B	3.3B	5.5B	5.4B	5.4B	4.7B	6.5B	5.1B	4.4B	4.3B	3.7B
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-10.5B	-10.1B	-9.8B	-9.6B	-8.7B	-8.5B	-8B	-7.6B	-7.5B	-6.5B	-4.5B
Common Stock	3M	3M	3M	3M	3M	3M	3M	3M	3M	6M	6M	6M	6M	6M	6M	6M	6M	6M	6M	5M
Additional Paid-In Capital	5.6B	5.5B	5.4B	5.3B	5.3B	5.3B	5.3B	5.3B	5.3B	9.2B	9B	9B	8.7B	8.5B	8.3B	7.9B	7.6B	7.4B	7.1B	6.6B
Retained Earnings	1.4B	750M	782M	324M	348M	81M	-18M	-336M	-126M	6.1B	5.6B	6.5B	6.1B	5.5B	4.5B	3.4B	2.8B	2.8B	2.2B	1.5B
Accumulated Other Comprehensive Income/Loss	-226M	-305M	-327M	-347M	-282M	-522M	-514M	-408M	-352M	-503M	-401M	-334M	91M	-111M	116M	-88M	-185M	-178M	408M	29M
Total Stockholders' Equity	6.7B	5.9B	5.8B	5.3B	5.4B	4.9B	4.7B	4.6B	4.8B	4.2B	4.2B	5.3B	5.3B	5.2B	4.3B	3.2B	2.5B	2.6B	3.2B	3.6B
Total Equity	6.7B	5.9B	5.8B	5.3B	5.4B	4.9B	4.7B	4.6B	4.8B	4.2B	4.2B	5.3B	5.3B	5.2B	4.3B	3.2B	2.5B	2.6B	3.2B	3.7B
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4M	4M	3M	3M	3M	3M	3M	8M	8M	0.0	0.0	0.0	11M
SUMMARY
Total Liabilities & Equity	12.7B	11.8B	10.8B	10.5B	10.7B	9.6B	9.5B	8.5B	8.4B	7.8B	7.5B	10.8B	10.7B	10.5B	9.1B	9.7B	7.6B	7B	7.6B	7.4B
Total Investments	133M	175M	164M	195M	276M	158M	102M	68M	138M	135M	86M	96M	139M	109M	117M	142M	177M	230M	0.0	0.0
Total Debt	3.4B	3.6B	2.7B	2.8B	2.7B	2.4B	2.4B	1.8B	2B	1.9B	1.7B	1.7B	2.7B	2.4B	2.2B	3.7B	2.9B	2.1B	2.1B	1.5B
Net Debt	1.6B	2.2B	1.1B	1.7B	1.2B	918M	1B	-448M	-667M	-385M	-348M	-555M	24M	11M	-1.3B	1B	426M	720M	261M	-762M
Shares Outstanding	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208	283,524,208

SEC Filings

A - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q2 Q2	June 01, 2026	April 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	April 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 03, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	March 03, 2026	January 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	February 06, 2026	March 18, 2026	2026	View Filing

Showing 1 to 10 of 463 filings

Related Guides

Blog Categories

Continue your A research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.